Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTE: benralizumab in eosinophilic COPD with frequent exacerbations
2022-503050-39-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Nov 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-503050-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503050-39-00.